KR101168440B1 - 지질 캡슐화된 간섭 ｒｎａ - Google Patents

지질 캡슐화된 간섭 ｒｎａ Download PDF

Info

Publication number: KR101168440B1
Authority: KR; South Korea
Prior art keywords: nucleic acid; lipid; delete delete; particle; peg
Prior art date: 2003-07-16

Application number

KR1020067000992A

Other languages

English (en)

Korean (ko)

Other versions

KR20060028655A (ko

Inventor

이안 마클라클란

엘렌 그레이스 앰베지아

제임스 헤예스

Original Assignee

프로티바 바이오쎄라퓨틱스, 인코포레이티드

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-16

Filing date

2004-07-16

Publication date

2012-07-27

2004-07-16 Application filed by 프로티바 바이오쎄라퓨틱스, 인코포레이티드 filed Critical 프로티바 바이오쎄라퓨틱스, 인코포레이티드

2006-03-30 Publication of KR20060028655A publication Critical patent/KR20060028655A/ko

2012-07-27 Application granted granted Critical

2012-07-27 Publication of KR101168440B1 publication Critical patent/KR101168440B1/ko

Links

150000002632 lipids Chemical class 0.000 title claims description 220
230000002452 interceptive effect Effects 0.000 title description 28
239000002245 particle Substances 0.000 claims abstract description 248
239000000203 mixture Substances 0.000 claims abstract description 136
108020004459 Small interfering RNA Proteins 0.000 claims abstract description 125
238000000034 method Methods 0.000 claims abstract description 116
230000014509 gene expression Effects 0.000 claims abstract description 71
230000030279 gene silencing Effects 0.000 claims abstract description 12
108090000623 proteins and genes Proteins 0.000 claims description 114
229920001223 polyethylene glycol Polymers 0.000 claims description 91
210000004027 cell Anatomy 0.000 claims description 86
-1 cationic lipid Chemical class 0.000 claims description 67
238000012384 transportation and delivery Methods 0.000 claims description 47
125000002091 cationic group Chemical group 0.000 claims description 45
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 44
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 26
201000010099 disease Diseases 0.000 claims description 26
GLGLUQVVDHRLQK-WRBBJXAJSA-N n,n-dimethyl-2,3-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/CCCCCCCC GLGLUQVVDHRLQK-WRBBJXAJSA-N 0.000 claims description 26
229910052757 nitrogen Inorganic materials 0.000 claims description 23
235000012000 cholesterol Nutrition 0.000 claims description 22
238000001727 in vivo Methods 0.000 claims description 22
125000003729 nucleotide group Chemical group 0.000 claims description 21
208000030159 metabolic disease Diseases 0.000 claims description 20
239000002773 nucleotide Substances 0.000 claims description 20
239000007864 aqueous solution Substances 0.000 claims description 19
230000002776 aggregation Effects 0.000 claims description 17
238000004220 aggregation Methods 0.000 claims description 17
239000002202 Polyethylene glycol Substances 0.000 claims description 15
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 15
208000035475 disorder Diseases 0.000 claims description 14
125000000217 alkyl group Chemical group 0.000 claims description 12
230000015556 catabolic process Effects 0.000 claims description 12
238000006731 degradation reaction Methods 0.000 claims description 12
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims description 10
230000002018 overexpression Effects 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 9
150000003904 phospholipids Chemical class 0.000 claims description 9
229920006395 saturated elastomer Polymers 0.000 claims description 9
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 8
230000003834 intracellular effect Effects 0.000 claims description 8
KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims description 7
208000005623 Carcinogenesis Diseases 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 7
101710163270 Nuclease Proteins 0.000 claims description 7
230000036952 cancer formation Effects 0.000 claims description 7
231100000504 carcinogenesis Toxicity 0.000 claims description 7
208000036142 Viral infection Diseases 0.000 claims description 6
230000004083 survival effect Effects 0.000 claims description 6
230000009385 viral infection Effects 0.000 claims description 6
230000001413 cellular effect Effects 0.000 claims description 5
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
108091028664 Ribonucleotide Proteins 0.000 claims description 4
PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims description 4
239000002336 ribonucleotide Substances 0.000 claims description 4
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
230000009466 transformation Effects 0.000 claims description 4
208000032928 Dyslipidaemia Diseases 0.000 claims description 3
208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
UAKOZKUVZRMOFN-JDVCJPALSA-M dimethyl-bis[(z)-octadec-9-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CCCCCCCC\C=C/CCCCCCCC UAKOZKUVZRMOFN-JDVCJPALSA-M 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
208000016097 disease of metabolism Diseases 0.000 claims 1
210000005229 liver cell Anatomy 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
150000007523 nucleic acids Chemical class 0.000 description 136
102000039446 nucleic acids Human genes 0.000 description 121
108020004707 nucleic acids Proteins 0.000 description 121
239000000243 solution Substances 0.000 description 71
108091032973 (ribonucleotides)n+m Proteins 0.000 description 66
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 59
206010028980 Neoplasm Diseases 0.000 description 52
239000013612 plasmid Substances 0.000 description 52
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 44
239000003599 detergent Substances 0.000 description 43
239000005089 Luciferase Substances 0.000 description 41
239000002502 liposome Substances 0.000 description 41
239000000047 product Substances 0.000 description 37
238000009472 formulation Methods 0.000 description 36
108060001084 Luciferase Proteins 0.000 description 33
150000001875 compounds Chemical class 0.000 description 28
241000699670 Mus sp. Species 0.000 description 27
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 27
238000000338 in vitro Methods 0.000 description 26
229940106189 ceramide Drugs 0.000 description 25
102000040650 (ribonucleotides)n+m Human genes 0.000 description 24
108020004414 DNA Proteins 0.000 description 24
239000003960 organic solvent Substances 0.000 description 24
238000002360 preparation method Methods 0.000 description 24
KPNIMSUWPAYOQV-UHFFFAOYSA-N 1,2-di(tetradecoxy)propan-1-amine Chemical compound CCCCCCCCCCCCCCOC(C)C(N)OCCCCCCCCCCCCCC KPNIMSUWPAYOQV-UHFFFAOYSA-N 0.000 description 23
238000003556 assay Methods 0.000 description 23
238000001990 intravenous administration Methods 0.000 description 23
238000006243 chemical reaction Methods 0.000 description 22
210000004185 liver Anatomy 0.000 description 22
210000001519 tissue Anatomy 0.000 description 22
238000002156 mixing Methods 0.000 description 21
239000002953 phosphate buffered saline Substances 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
230000000087 stabilizing effect Effects 0.000 description 19
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
238000002347 injection Methods 0.000 description 18
239000007924 injection Substances 0.000 description 18
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
125000002252 acyl group Chemical group 0.000 description 17
238000009396 hybridization Methods 0.000 description 16
102000004169 proteins and genes Human genes 0.000 description 16
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 15
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 15
230000000694 effects Effects 0.000 description 15
238000004809 thin layer chromatography Methods 0.000 description 15
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
108091028043 Nucleic acid sequence Proteins 0.000 description 14
210000004072 lung Anatomy 0.000 description 14
230000007935 neutral effect Effects 0.000 description 14
210000000056 organ Anatomy 0.000 description 14
235000018102 proteins Nutrition 0.000 description 14
239000000523 sample Substances 0.000 description 14
239000002904 solvent Substances 0.000 description 14
239000007858 starting material Substances 0.000 description 14
AZJPSRIYSFXHTR-UHFFFAOYSA-N 2-[2,3-di(tetradecoxy)propyl]isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CC(COCCCCCCCCCCCCCC)OCCCCCCCCCCCCCC)C(=O)C2=C1 AZJPSRIYSFXHTR-UHFFFAOYSA-N 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
238000000502 dialysis Methods 0.000 description 13
239000012071 phase Substances 0.000 description 13
150000008104 phosphatidylethanolamines Chemical class 0.000 description 13
229920000642 polymer Polymers 0.000 description 13
235000002639 sodium chloride Nutrition 0.000 description 13
238000001890 transfection Methods 0.000 description 13
239000000232 Lipid Bilayer Substances 0.000 description 12
239000003446 ligand Substances 0.000 description 12
239000012528 membrane Substances 0.000 description 12
238000003752 polymerase chain reaction Methods 0.000 description 12
210000002966 serum Anatomy 0.000 description 12
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 11
230000003321 amplification Effects 0.000 description 11
210000004369 blood Anatomy 0.000 description 11
239000008280 blood Substances 0.000 description 11
238000005538 encapsulation Methods 0.000 description 11
230000002209 hydrophobic effect Effects 0.000 description 11
238000003199 nucleic acid amplification method Methods 0.000 description 11
239000000725 suspension Substances 0.000 description 11
238000013518 transcription Methods 0.000 description 11
230000035897 transcription Effects 0.000 description 11
238000011282 treatment Methods 0.000 description 11
150000001783 ceramides Chemical class 0.000 description 10
150000001982 diacylglycerols Chemical class 0.000 description 10
238000003818 flash chromatography Methods 0.000 description 10
208000019423 liver disease Diseases 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
230000035508 accumulation Effects 0.000 description 9
238000009825 accumulation Methods 0.000 description 9
230000000295 complement effect Effects 0.000 description 9
239000012153 distilled water Substances 0.000 description 9
239000000463 material Substances 0.000 description 9
108090000765 processed proteins & peptides Proteins 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 8
238000001514 detection method Methods 0.000 description 8
230000009368 gene silencing by RNA Effects 0.000 description 8
MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 8
239000012044 organic layer Substances 0.000 description 8
230000008569 process Effects 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
210000000952 spleen Anatomy 0.000 description 8
238000012385 systemic delivery Methods 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
150000001412 amines Chemical class 0.000 description 7
238000009826 distribution Methods 0.000 description 7
239000003937 drug carrier Substances 0.000 description 7
238000001476 gene delivery Methods 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
229910052943 magnesium sulfate Inorganic materials 0.000 description 7
235000019341 magnesium sulphate Nutrition 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
108020004999 messenger RNA Proteins 0.000 description 7
229920002647 polyamide Polymers 0.000 description 7
239000002243 precursor Substances 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
230000008685 targeting Effects 0.000 description 7
238000013519 translation Methods 0.000 description 7
230000003612 virological effect Effects 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
IAJHLVPJJCPWLF-UHFFFAOYSA-N 2,3-di(tetradecoxy)propan-1-ol Chemical compound CCCCCCCCCCCCCCOCC(CO)OCCCCCCCCCCCCCC IAJHLVPJJCPWLF-UHFFFAOYSA-N 0.000 description 6
WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 6
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
241000725303 Human immunodeficiency virus Species 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 6
239000004952 Polyamide Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
235000014113 dietary fatty acids Nutrition 0.000 description 6
MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 6
229930195729 fatty acid Natural products 0.000 description 6
239000000194 fatty acid Substances 0.000 description 6
210000002216 heart Anatomy 0.000 description 6
208000006454 hepatitis Diseases 0.000 description 6
231100000283 hepatitis Toxicity 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
230000002035 prolonged effect Effects 0.000 description 6
238000004513 sizing Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000007787 solid Substances 0.000 description 6
230000009885 systemic effect Effects 0.000 description 6
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 5
WPHZWWGBPJAPCW-UHFFFAOYSA-N 1-(3-prop-2-enoxy-2-tetradecoxypropoxy)tetradecane Chemical compound CCCCCCCCCCCCCCOCC(COCC=C)OCCCCCCCCCCCCCC WPHZWWGBPJAPCW-UHFFFAOYSA-N 0.000 description 5
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 5
RWKUXQNLWDTSLO-GWQJGLRPSA-N N-hexadecanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC RWKUXQNLWDTSLO-GWQJGLRPSA-N 0.000 description 5
229920002873 Polyethylenimine Polymers 0.000 description 5
230000027455 binding Effects 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 5
230000001186 cumulative effect Effects 0.000 description 5
208000037765 diseases and disorders Diseases 0.000 description 5
230000003828 downregulation Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
150000004665 fatty acids Chemical class 0.000 description 5
238000001415 gene therapy Methods 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
229910052739 hydrogen Inorganic materials 0.000 description 5
238000011534 incubation Methods 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
239000011630 iodine Substances 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000002609 medium Substances 0.000 description 5
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
241000894007 species Species 0.000 description 5
238000012360 testing method Methods 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
102000007592 Apolipoproteins Human genes 0.000 description 4
108010071619 Apolipoproteins Proteins 0.000 description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 4
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
150000001413 amino acids Chemical group 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
125000000129 anionic group Chemical group 0.000 description 4
239000002585 base Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
229930183167 cerebroside Natural products 0.000 description 4
238000000576 coating method Methods 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
230000004927 fusion Effects 0.000 description 4
210000003494 hepatocyte Anatomy 0.000 description 4
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
230000004957 immunoregulator effect Effects 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
238000001802 infusion Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
239000010410 layer Substances 0.000 description 4
125000005647 linker group Chemical group 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
239000000693 micelle Substances 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
238000007899 nucleic acid hybridization Methods 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
235000021317 phosphate Nutrition 0.000 description 4
229940067605 phosphatidylethanolamines Drugs 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000004055 small Interfering RNA Substances 0.000 description 4
230000003595 spectral effect Effects 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000036326 tumor accumulation Effects 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 3
PAZGBAOHGQRCBP-ZCXUNETKSA-N 1-Palmitoyl-2-oleoylglycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-ZCXUNETKSA-N 0.000 description 3
VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 3
CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 3
108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 3
102000016911 Deoxyribonucleases Human genes 0.000 description 3
108010053770 Deoxyribonucleases Proteins 0.000 description 3
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
108010067770 Endopeptidase K Proteins 0.000 description 3
108090000394 Erythropoietin Proteins 0.000 description 3
102000003951 Erythropoietin Human genes 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
208000005176 Hepatitis C Diseases 0.000 description 3
108010050904 Interferons Proteins 0.000 description 3
102000014150 Interferons Human genes 0.000 description 3
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 3
108010004729 Phycoerythrin Proteins 0.000 description 3
229930182558 Sterol Natural products 0.000 description 3
102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 3
108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
229920004890 Triton X-100 Polymers 0.000 description 3
241000700605 Viruses Species 0.000 description 3
CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
125000001931 aliphatic group Chemical group 0.000 description 3
230000002491 angiogenic effect Effects 0.000 description 3
238000000137 annealing Methods 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
108010005774 beta-Galactosidase Proteins 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
239000011616 biotin Substances 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
239000000969 carrier Substances 0.000 description 3
229920006317 cationic polymer Polymers 0.000 description 3
230000010307 cell transformation Effects 0.000 description 3
238000004040 coloring Methods 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
235000013601 eggs Nutrition 0.000 description 3
229940105423 erythropoietin Drugs 0.000 description 3
ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000012226 gene silencing method Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
150000002431 hydrogen Chemical class 0.000 description 3
229920001477 hydrophilic polymer Polymers 0.000 description 3
230000028993 immune response Effects 0.000 description 3
238000007901 in situ hybridization Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
102000004311 liver X receptors Human genes 0.000 description 3
108090000865 liver X receptors Proteins 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
229920001427 mPEG Polymers 0.000 description 3
238000005259 measurement Methods 0.000 description 3
244000000010 microbial pathogen Species 0.000 description 3
244000005700 microbiome Species 0.000 description 3
238000013508 migration Methods 0.000 description 3
230000005012 migration Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical group CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
229910052698 phosphorus Inorganic materials 0.000 description 3
229920000747 poly(lactic acid) Polymers 0.000 description 3
239000004626 polylactic acid Substances 0.000 description 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
150000004671 saturated fatty acids Chemical class 0.000 description 3
235000003441 saturated fatty acids Nutrition 0.000 description 3
238000005549 size reduction Methods 0.000 description 3
150000003432 sterols Chemical class 0.000 description 3
235000003702 sterols Nutrition 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000007910 systemic administration Methods 0.000 description 3
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
150000004670 unsaturated fatty acids Chemical class 0.000 description 3
235000021122 unsaturated fatty acids Nutrition 0.000 description 3
JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 2
SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
KOFZTCSTGIWCQG-UHFFFAOYSA-N 1-bromotetradecane Chemical compound CCCCCCCCCCCCCCBr KOFZTCSTGIWCQG-UHFFFAOYSA-N 0.000 description 2
DPVZNLNBPGLMRJ-UHFFFAOYSA-N 2,3-di(tetradecoxy)propan-1-amine Chemical compound CCCCCCCCCCCCCCOCC(CN)OCCCCCCCCCCCCCC DPVZNLNBPGLMRJ-UHFFFAOYSA-N 0.000 description 2
HWKZZBGCWOVZRS-UHFFFAOYSA-N 2,3-di(tetradecoxy)propyl methanesulfonate Chemical compound CCCCCCCCCCCCCCOCC(COS(C)(=O)=O)OCCCCCCCCCCCCCC HWKZZBGCWOVZRS-UHFFFAOYSA-N 0.000 description 2
PVVTWNMXEHROIA-UHFFFAOYSA-N 2-(3-hydroxypropyl)-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(CCCO)=NC(=O)C2=C1 PVVTWNMXEHROIA-UHFFFAOYSA-N 0.000 description 2
NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 2
101710142585 50S ribosomal protein 6, chloroplastic Proteins 0.000 description 2
SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 description 2
102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 2
108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 2
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
241000726103 Atta Species 0.000 description 2
102100026189 Beta-galactosidase Human genes 0.000 description 2
102100038495 Bile acid receptor Human genes 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
101710091045 Envelope protein Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
108060002716 Exonuclease Proteins 0.000 description 2
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
OOFLZRMKTMLSMH-UHFFFAOYSA-N H4atta Chemical compound OC(=O)CN(CC(O)=O)CC1=CC=CC(C=2N=C(C=C(C=2)C=2C3=CC=CC=C3C=C3C=CC=CC3=2)C=2N=C(CN(CC(O)=O)CC(O)=O)C=CC=2)=N1 OOFLZRMKTMLSMH-UHFFFAOYSA-N 0.000 description 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
208000005331 Hepatitis D Diseases 0.000 description 2
206010019773 Hepatitis G Diseases 0.000 description 2
229920000209 Hexadimethrine bromide Polymers 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
241000701806 Human papillomavirus Species 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
102100034028 Membrane-bound transcription factor site-1 protease Human genes 0.000 description 2
102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
108010016731 PPAR gamma Proteins 0.000 description 2
108091093037 Peptide nucleic acid Proteins 0.000 description 2
102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 2
108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
241000288906 Primates Species 0.000 description 2
101710188315 Protein X Proteins 0.000 description 2
108700008625 Reporter Genes Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
108091005487 SCARB1 Proteins 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 2
108700019146 Transgenes Proteins 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
238000010936 aqueous wash Methods 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
230000006472 autoimmune response Effects 0.000 description 2
239000011324 bead Substances 0.000 description 2
239000003012 bilayer membrane Substances 0.000 description 2
238000002306 biochemical method Methods 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
238000007664 blowing Methods 0.000 description 2
239000012267 brine Substances 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 2
150000001784 cerebrosides Chemical class 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
239000013068 control sample Substances 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
239000013058 crude material Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
239000000412 dendrimer Substances 0.000 description 2
229920000736 dendritic polymer Polymers 0.000 description 2
239000005547 deoxyribonucleotide Substances 0.000 description 2
125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
230000000368 destabilizing effect Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
102000013165 exonuclease Human genes 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000002073 fluorescence micrograph Methods 0.000 description 2
238000000799 fluorescence microscopy Methods 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
230000000799 fusogenic effect Effects 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
229950004781 gemcabene Drugs 0.000 description 2
238000007429 general method Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
210000005003 heart tissue Anatomy 0.000 description 2
208000005252 hepatitis A Diseases 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
201000010284 hepatitis E Diseases 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
239000011261 inert gas Substances 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 2
238000007834 ligase chain reaction Methods 0.000 description 2
238000001638 lipofection Methods 0.000 description 2
238000003670 luciferase enzyme activity assay Methods 0.000 description 2
239000012931 lyophilized formulation Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 2
108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
HIYQUCBXYVGHDN-UHFFFAOYSA-N n'-[2,3-di(tetradecoxy)propyl]butanediamide Chemical compound CCCCCCCCCCCCCCOCC(CNC(=O)CCC(N)=O)OCCCCCCCCCCCCCC HIYQUCBXYVGHDN-UHFFFAOYSA-N 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
239000003002 pH adjusting agent Substances 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920000724 poly(L-arginine) polymer Polymers 0.000 description 2
229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
229920000083 poly(allylamine) Polymers 0.000 description 2
229920000768 polyamine Polymers 0.000 description 2
239000004633 polyglycolic acid Substances 0.000 description 2
108010055896 polyornithine Proteins 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 2
239000000843 powder Substances 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
238000000746 purification Methods 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
125000002652 ribonucleotide group Chemical group 0.000 description 2
238000003345 scintillation counting Methods 0.000 description 2
108010048078 site 1 membrane-bound transcription factor peptidase Proteins 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
238000000527 sonication Methods 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
150000003408 sphingolipids Chemical class 0.000 description 2
239000007921 spray Substances 0.000 description 2
125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
239000013598 vector Substances 0.000 description 2
238000011179 visual inspection Methods 0.000 description 2
239000001993 wax Substances 0.000 description 2
JVAZJLFFSJARQM-RMPHRYRLSA-N (2r,3r,4s,5s,6r)-2-hexoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical group CCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JVAZJLFFSJARQM-RMPHRYRLSA-N 0.000 description 1
ZWEVPYNPHSPIFU-AUGHYPCGSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-n-[3-[3-[[(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]propyl-[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenan Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)N(CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C)[C@@]2(C)[C@@H](O)C1 ZWEVPYNPHSPIFU-AUGHYPCGSA-N 0.000 description 1
QFAPUKLCALRPLH-UXXRCYHCSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-nonoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QFAPUKLCALRPLH-UXXRCYHCSA-N 0.000 description 1
RRBGTUQJDFBWNN-MUGJNUQGSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O RRBGTUQJDFBWNN-MUGJNUQGSA-N 0.000 description 1
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical class CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
WSULSMOGMLRGKU-UHFFFAOYSA-N 1-bromooctadecane Chemical compound CCCCCCCCCCCCCCCCCCBr WSULSMOGMLRGKU-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
BVKFQEAERCHBTG-UHFFFAOYSA-N 17,18,19-trihydroxypentatriacontane-16,20-dione Chemical compound CCCCCCCCCCCCCCCC(=O)C(O)C(O)C(O)C(=O)CCCCCCCCCCCCCCC BVKFQEAERCHBTG-UHFFFAOYSA-N 0.000 description 1
VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
JHWIEAWILPSRMU-UHFFFAOYSA-N 2-methyl-3-pyrimidin-4-ylpropanoic acid Chemical compound OC(=O)C(C)CC1=CC=NC=N1 JHWIEAWILPSRMU-UHFFFAOYSA-N 0.000 description 1
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
PEAJXAZCGDWDGS-CNZCJKERSA-N 3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate;(3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 PEAJXAZCGDWDGS-CNZCJKERSA-N 0.000 description 1
PAKCOSURAUIXFG-UHFFFAOYSA-N 3-prop-2-enoxypropane-1,2-diol Chemical compound OCC(O)COCC=C PAKCOSURAUIXFG-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
LIFHMKCDDVTICL-UHFFFAOYSA-N 6-(chloromethyl)phenanthridine Chemical compound C1=CC=C2C(CCl)=NC3=CC=CC=C3C2=C1 LIFHMKCDDVTICL-UHFFFAOYSA-N 0.000 description 1
DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 description 1
108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
102000018616 Apolipoproteins B Human genes 0.000 description 1
108010027006 Apolipoproteins B Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
108060000903 Beta-catenin Proteins 0.000 description 1
102000015735 Beta-catenin Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101710117545 C protein Proteins 0.000 description 1
QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000283707 Capra Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
101710139375 Corneodesmosin Proteins 0.000 description 1
102000016736 Cyclin Human genes 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
102000011724 DNA Repair Enzymes Human genes 0.000 description 1
108010076525 DNA Repair Enzymes Proteins 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108700037122 EWS-FLI fusion Proteins 0.000 description 1
102000009024 Epidermal Growth Factor Human genes 0.000 description 1
241000283086 Equidae Species 0.000 description 1
101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000531123 GB virus C Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 description 1
101710125793 Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
102100026720 Interferon beta Human genes 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
LNXBEIZREVRNTF-UHFFFAOYSA-N Lifibrol Chemical compound C1=CC(C(C)(C)C)=CC=C1CCC(O)COC1=CC=C(C(O)=O)C=C1 LNXBEIZREVRNTF-UHFFFAOYSA-N 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
102100030817 Liver carboxylesterase 1 Human genes 0.000 description 1
101710181187 Liver carboxylesterase 1 Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
108700041567 MDR Genes Proteins 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108060004795 Methyltransferase Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710181008 P protein Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229940126033 PPAR agonist Drugs 0.000 description 1
241001494479 Pecora Species 0.000 description 1
101710177166 Phosphoprotein Proteins 0.000 description 1
244000134552 Plantago ovata Species 0.000 description 1
235000003421 Plantago ovata Nutrition 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
239000009223 Psyllium Substances 0.000 description 1
102000014450 RNA Polymerase III Human genes 0.000 description 1
108010078067 RNA Polymerase III Proteins 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
102000003661 Ribonuclease III Human genes 0.000 description 1
108010057163 Ribonuclease III Proteins 0.000 description 1
102000004167 Ribonuclease P Human genes 0.000 description 1
108090000621 Ribonuclease P Proteins 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
VJEMOEYSQDKAQF-MJKDWHOWSA-N Saikosaponin C Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2C([C@H]3[C@](C4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)C)O[C@@H]1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VJEMOEYSQDKAQF-MJKDWHOWSA-N 0.000 description 1
KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 1
VSVPCEFIECVNTB-UHFFFAOYSA-N Saikosaponin c Natural products CC1OC(OC2C(O)C(O)C(OC3CCC4(C)C(C3)C(C)(C)CC5(C)C4C=CC67OCC8(CCC(C)(C)CC68)C(O)CC57C)OC2COC9OC(CO)C(O)C(O)C9O)C(O)C(O)C1O VSVPCEFIECVNTB-UHFFFAOYSA-N 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
102000039471 Small Nuclear RNA Human genes 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
108010073771 Soybean Proteins Proteins 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
RKSMVPNZHBRNNS-UHFFFAOYSA-N Succinobucol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(SC(C)(C)SC=2C=C(C(OC(=O)CCC(O)=O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 RKSMVPNZHBRNNS-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
239000008049 TAE buffer Substances 0.000 description 1
108700019889 TEL-AML1 fusion Proteins 0.000 description 1
108010017842 Telomerase Proteins 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102400001320 Transforming growth factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
239000007984 Tris EDTA buffer Substances 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004896 Triton X-405 Polymers 0.000 description 1
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
101710086987 X protein Proteins 0.000 description 1
YVPOVOVZCOOSBQ-AXHZAXLDSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2s)-2-methylbutanoate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 YVPOVOVZCOOSBQ-AXHZAXLDSA-N 0.000 description 1
PNAMDJVUJCJOIX-IUNFJCKHSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate;(3r,4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-IUNFJCKHSA-N 0.000 description 1
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
FGYYWCMRFGLJOB-MQWKRIRWSA-N [2,3-dihydroxypropoxy(hydroxy)phosphoryl] (2s)-2,6-diaminohexanoate Chemical compound NCCCC[C@H](N)C(=O)OP(O)(=O)OCC(O)CO FGYYWCMRFGLJOB-MQWKRIRWSA-N 0.000 description 1
NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
VUBTYKDZOQNADH-UHFFFAOYSA-N acetyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)=O VUBTYKDZOQNADH-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229960003526 acipimox Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
229960001997 adefovir Drugs 0.000 description 1
WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
229940093740 amino acid and derivative Drugs 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
230000002547 anomalous effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000000883 anti-obesity agent Substances 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940125710 antiobesity agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
210000004507 artificial chromosome Anatomy 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
229960005370 atorvastatin Drugs 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
229920000080 bile acid sequestrant Polymers 0.000 description 1
229940096699 bile acid sequestrants Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
101150039352 can gene Proteins 0.000 description 1
238000005251 capillar electrophoresis Methods 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001720 carbohydrates Chemical group 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
ZDKCXSMMRXSSDE-UHFFFAOYSA-N chikusakoside II Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C67COC5(C6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)OC1COC1C(O)C(O)C(O)C(CO)O1 ZDKCXSMMRXSSDE-UHFFFAOYSA-N 0.000 description 1
230000001906 cholesterol absorption Effects 0.000 description 1
239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
239000005516 coenzyme A Substances 0.000 description 1
229940093530 coenzyme a Drugs 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229910000365 copper sulfate Inorganic materials 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
150000001985 dialkylglycerols Chemical class 0.000 description 1
235000001434 dietary modification Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000002296 dynamic light scattering Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000009088 enzymatic function Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
229960000815 ezetimibe Drugs 0.000 description 1
229940054572 ezetimibe / simvastatin Drugs 0.000 description 1
229960004396 famciclovir Drugs 0.000 description 1
GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 description 1
150000002339 glycosphingolipids Chemical class 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
CMYGERBJJJPWHH-UHFFFAOYSA-N heptacosane-13,14,15-triol Chemical compound CCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCC CMYGERBJJJPWHH-UHFFFAOYSA-N 0.000 description 1
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
NIDYWHLDTIVRJT-UJPOAAIJSA-N heptyl-β-d-glucopyranoside Chemical group CCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NIDYWHLDTIVRJT-UJPOAAIJSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
150000007857 hydrazones Chemical class 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000012296 in situ hybridization assay Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
210000002977 intracellular fluid Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
238000002955 isolation Methods 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
229960001627 lamivudine Drugs 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229950000716 lifibrol Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000003595 mist Substances 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 1
GXWGFBCFXATZLY-PSGJNUPMSA-N n,n-bis[3-[[(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]propyl]octanamide Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)NCCCN(C(=O)CCCCCCC)CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GXWGFBCFXATZLY-PSGJNUPMSA-N 0.000 description 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
GCRLIVCNZWDCDE-SJXGUFTOSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]nonanamide Chemical compound CCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GCRLIVCNZWDCDE-SJXGUFTOSA-N 0.000 description 1
SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
229940110831 niacin / simvastatin Drugs 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
KOZCGIRYBYLSKC-UHFFFAOYSA-N nonatriacontane-19,20,21-triol Chemical compound CCCCCCCCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCCCCCCCC KOZCGIRYBYLSKC-UHFFFAOYSA-N 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
238000007826 nucleic acid assay Methods 0.000 description 1
239000002417 nutraceutical Substances 0.000 description 1
235000021436 nutraceutical agent Nutrition 0.000 description 1
229940038580 oat bran Drugs 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000000668 oral spray Substances 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000002357 osmotic agent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
150000002948 pantothenic acids Chemical class 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000012247 phenotypical assay Methods 0.000 description 1
150000008298 phosphoramidates Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229960001109 policosanol Drugs 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
150000008442 polyphenolic compounds Chemical class 0.000 description 1
235000013824 polyphenols Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-M pravastatin(1-) Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-M 0.000 description 1
230000013823 prenylation Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
229940070687 psyllium Drugs 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000002601 radiography Methods 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
102000021501 regulatory RNA binding proteins Human genes 0.000 description 1
108091011116 regulatory RNA binding proteins Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
229940066675 ricinoleate Drugs 0.000 description 1
VJEMOEYSQDKAQF-UHFFFAOYSA-N saikogenin E 3-O-beta-D-glucopyranosyl-(1?6)-[alpha-L-rhamnopyranosyl-(1?4)]-beta-D-glucopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C67COC5(C6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)C)OC1COC1C(O)C(O)C(O)C(CO)O1 VJEMOEYSQDKAQF-UHFFFAOYSA-N 0.000 description 1
QLPRYZXNWYTFCI-UHFFFAOYSA-N saikosaponin D Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C2(C)CO)C(O)C(O)C1OC8OC(CO)C(O)C(O)C8O QLPRYZXNWYTFCI-UHFFFAOYSA-N 0.000 description 1
PQPVAGWUNWFCJE-UHFFFAOYSA-N saikosaponin a Natural products CC1OC(OC2CCC3(C)C(C2)C(C)(CO)CC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C(O)C(OC8OC(CO)C(O)C(O)C8O)C1O PQPVAGWUNWFCJE-UHFFFAOYSA-N 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
210000002363 skeletal muscle cell Anatomy 0.000 description 1
108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
229940001941 soy protein Drugs 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
208000002320 spinal muscular atrophy Diseases 0.000 description 1
238000009987 spinning Methods 0.000 description 1
239000004059 squalene synthase inhibitor Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
108010061115 tetralysine Proteins 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
239000006208 topical dosage form Substances 0.000 description 1
CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
229950004514 torcetrapib Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
108091006106 transcriptional activators Proteins 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
239000002691 unilamellar liposome Substances 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
239000000277 virosome Substances 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses

KR1020067000992A 2003-07-16 2004-07-16 지질 캡슐화된 간섭 ｒｎａ KR101168440B1 (ko)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US48814403P	2003-07-16	2003-07-16
US60/488,144		2003-07-16
US50327903P	2003-09-15	2003-09-15
US60/503,279		2003-09-15
US52940603P	2003-12-11	2003-12-11
US60/529,406		2003-12-11
PCT/CA2004/001051 WO2005007196A2 (en)	2003-07-16	2004-07-16	Lipid encapsulated interfering rna

Publications (2)

Publication Number	Publication Date
KR20060028655A KR20060028655A (ko)	2006-03-30
KR101168440B1 true KR101168440B1 (ko)	2012-07-27

Family

ID=34084527

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020067000992A KR101168440B1 (ko)	2003-07-16	2004-07-16	지질 캡슐화된 간섭 ｒｎａ

Country Status (13)

Country	Link
US (3)	US20050064595A1 (es)
EP (2)	EP2567693B1 (es)
JP (4)	JP4951338B2 (es)
KR (1)	KR101168440B1 (es)
CN (1)	CN101291653B (es)
AU (2)	AU2004257373B2 (es)
CA (1)	CA2532228C (es)
ES (1)	ES2559828T3 (es)
HK (1)	HK1123751A1 (es)
IL (2)	IL173052A (es)
NZ (1)	NZ544637A (es)
SG (1)	SG190613A1 (es)
WO (1)	WO2005007196A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2019212288A1 (ko) *	2018-05-04	2019-11-07	주식회사 삼양바이오팜	Messenger rna 전달용 고분자 나노입자 조성물 및 그 제조방법

Families Citing this family (366)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7935812B2 (en)	2002-02-20	2011-05-03	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
EP1519714B1 (en)	2002-06-28	2010-10-20	Protiva Biotherapeutics Inc.	Method and apparatus for producing liposomes
US9228186B2 (en)	2002-11-14	2016-01-05	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
EP2567693B1 (en) *	2003-07-16	2015-10-21	Protiva Biotherapeutics Inc.	Lipid encapsulated interfering RNA
NZ592917A (en) *	2003-09-15	2012-12-21	Protiva Biotherapeutics Inc	Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
EP1709195B1 (en) *	2003-12-19	2014-01-22	Novartis Vaccines and Diagnostics, Inc.	Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
ES2423060T3 (es)	2004-03-12	2013-09-17	Alnylam Pharmaceuticals, Inc.	Agentes iRNA que tienen como diana al VEGF
US20060014289A1 (en) *	2004-04-20	2006-01-19	Nastech Pharmaceutical Company Inc.	Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
US20060040882A1 (en) *	2004-05-04	2006-02-23	Lishan Chen	Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
AU2005251403B2 (en)	2004-06-07	2011-09-01	Arbutus Biopharma Corporation	Cationic lipids and methods of use
AU2005252273B2 (en)	2004-06-07	2011-04-28	Arbutus Biopharma Corporation	Lipid encapsulated interfering RNA
CA2572439A1 (en) *	2004-07-02	2006-01-12	Protiva Biotherapeutics, Inc.	Immunostimulatory sirna molecules and uses therefor
WO2006020182A2 (en) *	2004-07-16	2006-02-23	Smart Medical Technologies, Llc	Centrifuge system
GB0418172D0 (en) *	2004-08-13	2004-09-15	Ic Vec Ltd	Vector
JP2008509205A (ja) *	2004-08-13	2008-03-27	アイシー・ベック・リミテッド	ポリマー修飾ｓｉＲＮＡリポソームを含むベクター
ATE514776T1 (de)	2004-10-05	2011-07-15	California Inst Of Techn	Aptamer-regulierte nukleinsäuren und verwendungen davon
US9492400B2 (en)	2004-11-04	2016-11-15	Massachusetts Institute Of Technology	Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EP1828219A4 (en) *	2004-11-17	2008-07-23	Protiva Biotherapeutics Inc	ARNSI SILENCE OF APOLIPOPROTEIN B
US9393315B2 (en)	2011-06-08	2016-07-19	Nitto Denko Corporation	Compounds for targeting drug delivery and enhancing siRNA activity
WO2006074546A1 (en) *	2005-01-13	2006-07-20	Protiva Biotherapeutics, Inc.	Lipid encapsulated interfering rna
US7404969B2 (en)	2005-02-14	2008-07-29	Sirna Therapeutics, Inc.	Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2007086883A2 (en) *	2005-02-14	2007-08-02	Sirna Therapeutics, Inc.	Cationic lipids and formulated molecular compositions containing them
US20070213293A1 (en) *	2005-04-08	2007-09-13	Nastech Pharmaceutical Company Inc.	Rnai therapeutic for respiratory virus infection
US8895717B2 (en) *	2005-04-15	2014-11-25	The Board Of Regents Of The University Of Texas System	Delivery of siRNA by neutral lipid compositions
FR2885813B1 (fr) *	2005-05-19	2008-01-11	Oreal	Vectorisation de dsrna par des particules cationiques et leur utilisation sur modele de peau.
US9095630B2 (en)	2005-05-19	2015-08-04	L'oreal	Vectorization of dsRNA by cationic particles and use of same on a skin model
US20070054873A1 (en) *	2005-08-26	2007-03-08	Protiva Biotherapeutics, Inc.	Glucocorticoid modulation of nucleic acid-mediated immune stimulation
KR20080082956A (ko) *	2005-09-15	2008-09-12	노보솜 아게	양쪽성 리포솜의 개선 또는 양쪽성 리포솜에 관련된 개선
TW200800235A (en) *	2005-10-18	2008-01-01	Otsuka Pharma Co Ltd	Carrier composition for nucleic acid transport
US7838658B2 (en) *	2005-10-20	2010-11-23	Ian Maclachlan	siRNA silencing of filovirus gene expression
CA2628300C (en) *	2005-11-02	2018-04-17	Protiva Biotherapeutics, Inc.	Modified sirna molecules and uses thereof
US9267937B2 (en)	2005-12-15	2016-02-23	Massachusetts Institute Of Technology	System for screening particles
WO2008105773A2 (en)	2006-03-31	2008-09-04	Massachusetts Institute Of Technology	System for targeted delivery of therapeutic agents
CA2915441A1 (en)	2006-05-11	2007-11-22	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the pcsk9 gene
JP5630998B2 (ja)	2006-05-15	2014-11-26	マサチューセッツインスティテュートオブテクノロジー	機能的粒子のためのポリマー
US8598333B2 (en) *	2006-05-26	2013-12-03	Alnylam Pharmaceuticals, Inc.	SiRNA silencing of genes expressed in cancer
US7915399B2 (en)	2006-06-09	2011-03-29	Protiva Biotherapeutics, Inc.	Modified siRNA molecules and uses thereof
WO2007150030A2 (en)	2006-06-23	2007-12-27	Massachusetts Institute Of Technology	Microfluidic synthesis of organic nanoparticles
CA2660204A1 (en) *	2006-08-16	2008-02-21	Protiva Biotherapeutics, Inc.	Nucleic acid modulation of toll-like receptor-mediated immune stimulation
CA2661292A1 (en) *	2006-08-24	2008-02-28	British Columbia Cancer Agency Branch	Compositions and methods for treating myelosuppression
KR101129509B1 (ko)	2006-10-03	2012-04-13	알닐람 파마슈티칼스 인코포레이티드	지질 함유 조성물
AU2014200910B2 (en) *	2006-10-03	2017-02-09	Arbutus Biopharma Corporation	Lipid containing formulations
WO2008058291A2 (en)	2006-11-09	2008-05-15	California Institute Of Technology	Modular aptamer-regulated ribozymes
WO2008076324A2 (en) *	2006-12-14	2008-06-26	Novartis Ag	Compositions and methods to treat muscular & cardiovascular disorders
JP2010513354A (ja)	2006-12-19	2010-04-30	ノヴォソムアクチェンゲゼルシャフト	トランスフェクションエンハンサー要素を含む脂質および脂質集合体
US7985058B2 (en) *	2007-01-12	2011-07-26	Mark Gray	Method and apparatus for making uniformly sized particles
US20080171078A1 (en) *	2007-01-12	2008-07-17	Mark Gray	Uniformly sized liposomes
JP5415283B2 (ja) *	2007-02-07	2014-02-12	グラダリスインク．	シアル酸産生を調節し、遺伝性封入体ミオパチーを治療する方法及び組成物
WO2008098165A2 (en)	2007-02-09	2008-08-14	Massachusetts Institute Of Technology	Oscillating cell culture bioreactor
AU2008219165A1 (en) *	2007-02-16	2008-08-28	Merck Sharp & Dohme Corp.	Compositions and methods for potentiated activity of biologicaly active molecules
WO2008109432A2 (en) *	2007-03-02	2008-09-12	The Board Of Regents Of The University Of Texas System	Therapeutic targeting of interleukins using sirna in neutral liposomes
TWI428135B (zh) *	2007-03-26	2014-03-01	Hirofumi Takeuchi	And a carrier composition for quick-acting nucleic acid delivery
JP2010523595A (ja)	2007-04-04	2010-07-15	マサチューセッツインスティテュートオブテクノロジー	ポリ（アミノ酸）ターゲッティング部分
WO2008124634A1 (en) *	2007-04-04	2008-10-16	Massachusetts Institute Of Technology	Polymer-encapsulated reverse micelles
EP2494993B1 (en)	2007-05-04	2018-08-01	Marina Biotech, Inc.	Amino acid lipids and uses thereof
AU2008271756B2 (en) *	2007-06-29	2012-10-04	Statens Serum Institut	The use of monomycolyl glycerol (MMG) as an adjuvant
US20090082217A1 (en) *	2007-07-16	2009-03-26	California Institute Of Technology	Selection of nucleic acid-based sensor domains within nucleic acid switch platform
WO2009021325A1 (en)	2007-08-10	2009-02-19	British Columbia Cancer Agency Branch	Microrna compositions and methods for the treatment of myelogenous leukemia
US20120165387A1 (en)	2007-08-28	2012-06-28	Smolke Christina D	General composition framework for ligand-controlled RNA regulatory systems
US8367815B2 (en) *	2007-08-28	2013-02-05	California Institute Of Technology	Modular polynucleotides for ligand-controlled regulatory systems
US8865667B2 (en)	2007-09-12	2014-10-21	California Institute Of Technology	Higher-order cellular information processing devices
US10736848B2 (en)	2007-10-12	2020-08-11	Massachusetts Institute Of Technology	Vaccine nanotechnology
US7871985B2 (en)	2007-12-10	2011-01-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor VII gene
US9029524B2 (en) *	2007-12-10	2015-05-12	California Institute Of Technology	Signal activated RNA interference
CA2708354C (en) *	2007-12-13	2018-12-11	Polyplus-Transfection	Means for delivery of nucleic acids active for gene silencing using synthetic polymers
US9006191B2 (en) *	2007-12-27	2015-04-14	Protiva Biotherapeutics, Inc.	Silencing of polo-like kinase expression using interfering RNA
CA2713379A1 (en) *	2008-01-31	2009-11-05	Alnylam Pharmaceuticals, Inc.	Optimized methods for delivery of dsrna targeting the pcsk9 gene
EP2712926A2 (en) *	2008-03-05	2014-04-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP2770057A1 (en)	2008-04-15	2014-08-27	Protiva Biotherapeutics Inc.	Silencing of CSN5 gene expression using interfering RNA
HUE034483T2 (en)	2008-04-15	2018-02-28	Protiva Biotherapeutics Inc	New lipid preparations for introducing a nucleic acid
AU2009249403A1 (en) *	2008-05-19	2009-11-26	The University Of North Carolina At Chapel Hill	Methods and compositions comprising novel cationic lipids
WO2009149418A2 (en) *	2008-06-06	2009-12-10	Asuragen, Inc.	Novel compositions for the in vivo delivery of rnai agents
US8889640B1 (en) *	2008-06-20	2014-11-18	Jill P. Smith	Composition and method for the treatment of gastrin mediated cancers
US8815818B2 (en)	2008-07-18	2014-08-26	Rxi Pharmaceuticals Corporation	Phagocytic cell delivery of RNAI
US8034922B2 (en) *	2008-08-22	2011-10-11	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for modulating activity of capped small RNAs
EP2690175B1 (en)	2008-09-02	2016-12-28	Alnylam Pharmaceuticals, Inc.	Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression
US20100099738A1 (en) *	2008-09-10	2010-04-22	Abbott Laboratories	Polyethylene glycol lipid conjugates and uses thereof
WO2010033248A2 (en)	2008-09-22	2010-03-25	Rxi Pharmaceuticals Corporation	Neutral nanotransporters
WO2010036962A1 (en)	2008-09-25	2010-04-01	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
CA2984026C (en)	2008-10-09	2020-02-11	Arbutus Biopharma Corporation	Improved amino lipids and methods for the delivery of nucleic acids
WO2010042823A1 (en) *	2008-10-09	2010-04-15	Northeastern Universtiy	Multifunctional self-assembling polymeric nanosystems
US8343497B2 (en)	2008-10-12	2013-01-01	The Brigham And Women's Hospital, Inc.	Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en)	2008-10-12	2013-11-26	The Brigham And Women's Hospital, Inc.	Nicotine immunonanotherapeutics
US8343498B2 (en)	2008-10-12	2013-01-01	Massachusetts Institute Of Technology	Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en)	2008-10-12	2012-10-02	Massachusetts Institute Of Technology	Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
WO2010045512A2 (en)	2008-10-16	2010-04-22	Mdrna , Inc.	Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
HUE037875T2 (hu)	2008-10-20	2018-09-28	Alnylam Pharmaceuticals Inc	Transztiretin-expresszió gátlására szolgáló készítmények és eljárások
EP2350670B1 (en)	2008-10-30	2018-06-06	Peixuan Guo	Membrane-integrated viral dna-packaging motor protein connector biosensor for dna sequencing and other uses
NZ593618A (en)	2008-12-10	2013-02-22	Alnylam Pharmaceuticals Inc	Gnaq targeted dsrna compositions and methods for inhibiting expression
US10292932B2 (en) *	2008-12-26	2019-05-21	Samyang Biopharmaceuticals Corporation	Polymeric micelle particle comprising anionic drugs and method of preparing the same
JP5592897B2 (ja)	2008-12-26	2014-09-17	サムヤンバイオファーマシューティカルズコーポレイション	アニオン性薬物含有薬剤学的組成物及びその製造方法
WO2010078536A1 (en)	2009-01-05	2010-07-08	Rxi Pharmaceuticals Corporation	Inhibition of pcsk9 through rnai
EP2405921A4 (en)	2009-01-26	2013-05-22	Protiva Biotherapeutics Inc	COMPOSITIONS AND METHODS FOR INACTIVATION OF APOLIPOPROTEIN C-III EXPRESSION
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8329882B2 (en)	2009-02-18	2012-12-11	California Institute Of Technology	Genetic control of mammalian cells with synthetic RNA regulatory systems
US20120041051A1 (en)	2009-02-26	2012-02-16	Kevin Fitzgerald	Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
EP3424939A1 (en)	2009-03-02	2019-01-09	Alnylam Pharmaceuticals Inc.	Nucleic acid chemical modifications
US20120035247A1 (en)	2009-03-19	2012-02-09	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2408915A2 (en)	2009-03-19	2012-01-25	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010107952A2 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
MX2011009724A (es)	2009-03-19	2011-10-14	Merck Sharp & Dohme	Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen del factor de transcripcion basico de cierre de leucina 1 de homologia de btb y cnc 1, usando el listado de secuencias de acido nucleico corto de interferencia.
AU2010226434A1 (en) *	2009-03-20	2011-10-13	Egen, Inc.	Polyamine derivatives
US20120022142A1 (en)	2009-03-27	2012-01-26	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
AU2010229847A1 (en)	2009-03-27	2011-10-13	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA)
US20120022143A1 (en)	2009-03-27	2012-01-26	Merck Sharp & Dohme Corp	RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
JP2012521762A (ja)	2009-03-27	2012-09-20	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いた神経成長因子β鎖（ＮＧＦβ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120010272A1 (en)	2009-03-27	2012-01-12	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US9145555B2 (en)	2009-04-02	2015-09-29	California Institute Of Technology	Integrated—ligand-responsive microRNAs
AU2010245933B2 (en)	2009-05-05	2016-06-16	Arbutus Biopharma Corporation	Methods of delivering oligonucleotides to immune cells
CN102985548B (zh) *	2009-05-16	2016-10-26	崔坤元	用于递送治疗分子的包含阳离子两亲物和辅脂质的组合物
US9051567B2 (en)	2009-06-15	2015-06-09	Tekmira Pharmaceuticals Corporation	Methods for increasing efficacy of lipid formulated siRNA
MX2011013421A (es)	2009-06-15	2012-03-16	Alnylam Pharmaceuticals Inc	Arnds formulado con lipido de direccionamiento del gen pcsk9.
GB0910723D0 (en)	2009-06-22	2009-08-05	Sylentis Sau	Novel drugs for inhibition of gene expression
US9018187B2 (en)	2009-07-01	2015-04-28	Protiva Biotherapeutics, Inc.	Cationic lipids and methods for the delivery of therapeutic agents
JP5766188B2 (ja)	2009-07-01	2015-08-19	プロチババイオセラピューティクスインコーポレイティッド	固形腫瘍に治療剤を送達するための脂質製剤
WO2011000106A1 (en)	2009-07-01	2011-01-06	Protiva Biotherapeutics, Inc.	Improved cationic lipids and methods for the delivery of therapeutic agents
WO2011000108A1 (en)	2009-07-01	2011-01-06	Protiva Biotherapeutics, Inc.	Compositions and methods for silencing apolipoprotein b
WO2011011447A1 (en)	2009-07-20	2011-01-27	Protiva Biotherapeutics, Inc.	Compositions and methods for silencing ebola virus gene expression
AP2015008874A0 (en)	2009-08-14	2015-11-30	Alnylam Pharmaceuticals Inc	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
CN102481255B (zh)	2009-08-31	2015-04-22	那野伽利阿株式会社	颗粒组合物和含有其的医药组合物
WO2011038031A1 (en)	2009-09-22	2011-03-31	Alnylam Pharmaceuticals, Inc.	Dual targeting sirna agents
WO2011038160A2 (en)	2009-09-23	2011-03-31	Protiva Biotherapeutics, Inc.	Compositions and methods for silencing genes expressed in cancer
EP3252068A3 (en)	2009-10-12	2018-03-14	Larry J. Smith	Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011056883A1 (en)	2009-11-03	2011-05-12	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
EP3406720A1 (en)	2009-12-18	2018-11-28	Arrowhead Pharmaceuticals, Inc.	Organic compositions to treat hsf1-related diseases
US9198983B2 (en)	2010-01-25	2015-12-01	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of Mylip/Idol gene
CA2794187C (en)	2010-03-24	2020-07-14	Rxi Pharmaceuticals Corporation	Rna interference in ocular indications
WO2011119887A1 (en)	2010-03-24	2011-09-29	Rxi Pharmaceuticals Corporation	Rna interference in dermal and fibrotic indications
WO2011120053A1 (en)	2010-03-26	2011-09-29	Mersana Therapeutics, Inc.	Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2011120023A1 (en)	2010-03-26	2011-09-29	Marina Biotech, Inc.	Nucleic acid compounds for inhibiting survivin gene expression uses thereof
CA2792291A1 (en)	2010-03-29	2011-10-06	Kumamoto University	Sirna therapy for transthyretin (ttr) related ocular amyloidosis
US8455455B1 (en)	2010-03-31	2013-06-04	Protiva Biotherapeutics, Inc.	Compositions and methods for silencing genes involved in hemorrhagic fever
KR100986604B1 (ko) *	2010-04-01	2010-10-08	충남대학교산학협력단	신규한 아미노지질을 함유하는 에스아이알엔에이 수송용 유전자 조성물 및 제조방법
WO2011133584A2 (en)	2010-04-19	2011-10-27	Marina Biotech, Inc.	Nucleic acid compounds for inhibiting hras gene expression and uses thereof
AU2011244335B2 (en)	2010-04-23	2015-06-04	Arrowhead Pharmaceuticals, Inc.	Organic compositions to treat Beta-ENaC-related diseases
WO2011139842A2 (en)	2010-04-28	2011-11-10	Marina Biotech, Inc.	Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
WO2011141704A1 (en)	2010-05-12	2011-11-17	Protiva Biotherapeutics, Inc	Novel cyclic cationic lipids and methods of use
WO2011141705A1 (en)	2010-05-12	2011-11-17	Protiva Biotherapeutics, Inc.	Novel cationic lipids and methods of use thereof
KR101198715B1 (ko)	2010-05-14	2012-11-13	한국생명공학연구원	핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법
US9944671B2 (en)	2010-06-02	2018-04-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
US9006417B2 (en)	2010-06-30	2015-04-14	Protiva Biotherapeutics, Inc.	Non-liposomal systems for nucleic acid delivery
LT4005592T (lt)	2010-07-06	2023-01-10	Glaxosmithkline Biologicals S.A.	Viriono tipo tiekimo dalelės, skirtos savaime besireplikuojančioms rnr molekulėms
PT2590626E (pt)	2010-07-06	2016-01-26	Glaxosmithkline Biolog Sa	Lipossomas com lípidos que têm um valor de pka vantajoso para administração de arn
ES2646669T3 (es)	2010-07-06	2017-12-14	Glaxosmithkline Biologicals Sa	Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
US9770463B2 (en) *	2010-07-06	2017-09-26	Glaxosmithkline Biologicals Sa	Delivery of RNA to different cell types
PT2591114T (pt)	2010-07-06	2016-08-02	Glaxosmithkline Biologicals Sa	Imunização de mamíferos de grande porte com doses baixas de arn
US8518907B2 (en)	2010-08-02	2013-08-27	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
WO2012018881A2 (en) *	2010-08-03	2012-02-09	Alnylam Pharmaceuticals, Inc.	Methods and compositions for the regulation of rna
JP6106085B2 (ja)	2010-08-24	2017-03-29	サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
WO2012027467A1 (en)	2010-08-26	2012-03-01	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP4066857B1 (en)	2010-08-31	2022-12-21	GlaxoSmithKline Biologicals SA	Pegylated liposomes for delivery of immunogen-encoding rna
KR102162111B1 (ko)	2010-10-11	2020-10-07	노파르티스 아게	항원 전달 플랫폼
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012078967A2 (en)	2010-12-10	2012-06-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (epo) production
EP2648763A4 (en)	2010-12-10	2014-05-14	Alnylam Pharmaceuticals Inc	COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
MX360349B (es)	2011-03-29	2018-10-30	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
US9011903B2 (en)	2011-06-08	2015-04-21	Nitto Denko Corporation	Cationic lipids for therapeutic agent delivery formulations
US10196637B2 (en)	2011-06-08	2019-02-05	Nitto Denko Corporation	Retinoid-lipid drug carrier
EP3444348A1 (en)	2011-06-21	2019-02-20	Alnylam Pharmaceuticals, Inc.	Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
WO2012177947A2 (en)	2011-06-21	2012-12-27	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
AU2012272908A1 (en)	2011-06-21	2013-12-19	Alnylam Pharmaceuticals, Inc.	Assays and methods for determining activity of a therapeutic agent in a subject
EP3388068A1 (en)	2011-06-21	2018-10-17	Alnylam Pharmaceuticals, Inc.	Composition and methods for inhibition of expression of protein c (proc) genes
EP3597750B1 (en)	2011-06-23	2022-05-04	Alnylam Pharmaceuticals, Inc.	Serpina1 sirnas: compositions of matter and methods of treatment
EP2729165B1 (en)	2011-07-06	2017-11-08	GlaxoSmithKline Biologicals SA	Immunogenic combination compositions and uses thereof
JP2014526887A (ja)	2011-08-01	2014-10-09	アルナイラムファーマシューティカルズ，インコーポレイテッド	造血幹細胞移植の成功率を改善する方法
CA3185394A1 (en)	2011-09-02	2013-03-07	Arrowhead Pharmaceuticals, Inc.	Organic compositions to treat hsf1-related diseases
KR20140097143A (ko) *	2011-10-05	2014-08-06	프로티바 바이오쎄라퓨틱스, 인코포레이티드	알데히드 데히드로게나제를 침묵시키기 위한 조성물 및 방법
PL3301177T3 (pl)	2011-11-18	2020-08-24	Alnylam Pharmaceuticals, Inc.	ŚRODKI RNAi, KOMPOZYCJE I SPOSOBY ICH ZASTOSOWANIA DO LECZENIA CHORÓB ZWIĄZANYCH Z TRANSTYRETYNĄ (TTR)
EP3988537A1 (en)	2011-12-07	2022-04-27	Alnylam Pharmaceuticals, Inc.	Biodegradable lipids for the delivery of active agents
US9035039B2 (en)	2011-12-22	2015-05-19	Protiva Biotherapeutics, Inc.	Compositions and methods for silencing SMAD4
JP6158833B2 (ja)	2012-01-09	2017-07-05	アローヘッドファーマシューティカルズインコーポレイテッド	ベータ−カテニン関連疾患を処置するための有機組成物
NZ700075A (en)	2012-02-24	2016-05-27	Protiva Biotherapeutics Inc	Trialkyl cationic lipids and methods of use thereof
EP2833869B1 (en) *	2012-04-04	2020-10-28	Samyang Biopharmaceuticals Corporation	Method of preparing composition for delivering an anionic drug
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
WO2013166004A2 (en)	2012-05-02	2013-11-07	Novartis Ag	Organic compositions to treat kras-related diseases
US9687448B2 (en)	2012-12-07	2017-06-27	Alnylam Pharmaceuticals, Inc.	Nucleic acid lipid particle formulations
RU2721275C2 (ru)	2012-12-12	2020-05-18	Те Брод Инститьют, Инк.	Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии
US10227589B2 (en) *	2013-01-28	2019-03-12	Council Of Scientific And Industrial Research	Method for inhibiting tumor growth through RNA-interference using liposomally associated CDC20 siRNA
EP3845248A1 (en)	2013-02-05	2021-07-07	1Globe Health Institute LLC	Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
US20150366890A1 (en)	2013-02-25	2015-12-24	Trustees Of Boston University	Compositions and methods for treating fungal infections
AU2014223432A1 (en)	2013-02-28	2015-09-03	Arrowhead Pharmaceuticals, Inc.	Organic compositions to treat EPAS1-related diseases
WO2014182661A2 (en)	2013-05-06	2014-11-13	Alnylam Pharmaceuticals, Inc	Dosages and methods for delivering lipid formulated nucleic acid molecules
TWI492751B (zh) *	2013-06-04	2015-07-21	Univ Kaohsiung Medical	柴胡皂苷製備之醫藥組合物、其用途及其製備方法
AU2014281030B2 (en)	2013-06-17	2020-07-09	Massachusetts Institute Of Technology	Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
DK3011031T3 (da)	2013-06-17	2020-12-21	Broad Inst Inc	Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi
MX2015017313A (es)	2013-06-17	2016-11-25	Broad Inst Inc	Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
WO2015011633A1 (en)	2013-07-23	2015-01-29	Protiva Biotherapeutics, Inc.	Compositions and methods for delivering messenger rna
TWI669393B (zh)	2013-10-02	2019-08-21	艾爾妮蘭製藥公司	抑制ｌｅｃｔ２基因表現之組合物及方法
EA036477B1 (ru)	2013-10-04	2020-11-16	Элнилэм Фармасьютикалз, Инк.	Композиции и способы ингибирования экспрессии гена alas1
WO2015051135A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Organic compositions to treat hepcidin-related diseases
WO2015074010A2 (en)	2013-11-18	2015-05-21	Beth Israel Deaconess Medical Center, Inc.	Compositions and methods for cardiac regeneration
EP3077050B1 (en)	2013-12-04	2020-10-21	Phio Pharmaceuticals Corp.	Methods for treatment of wound healing utilizing chemically modified oligonucleotides
SG10201804977UA (en)	2013-12-12	2018-07-30	Broad Inst Inc	Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Particle Delivery Components
EP4219699A1 (en)	2013-12-12	2023-08-02	The Broad Institute, Inc.	Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
WO2015089486A2 (en)	2013-12-12	2015-06-18	The Broad Institute Inc.	Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
MX2016007324A (es)	2013-12-12	2017-03-06	Broad Inst Inc	Suministro, uso y aplicaciones terapeuticas de los sistemas y composiciones crispr-cas para actuar sobre hbv y trastornos y enfermedades virales.
CA2932478A1 (en)	2013-12-12	2015-06-18	Massachusetts Institute Of Technology	Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
AU2014362248A1 (en)	2013-12-12	2016-06-16	Massachusetts Institute Of Technology	Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
WO2015168108A2 (en)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treating cancer using nucleic targeting mdm2 or mycn
CA2947619A1 (en)	2014-05-01	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
AU2015274367B2 (en)	2014-06-13	2020-11-26	Beth Israel Deaconess Medical Center, Inc.	Products and methods to isolate mitochondria
EP3766916B1 (en)	2014-06-25	2022-09-28	Acuitas Therapeutics Inc.	Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3169784B1 (en)	2014-07-16	2020-06-10	Arrowhead Pharmaceuticals, Inc.	Rnai compositions to treat apoc3-related diseases
EP3686279B1 (en)	2014-08-17	2023-01-04	The Broad Institute, Inc.	Genome editing using cas9 nickases
KR102631505B1 (ko)	2014-08-29	2024-02-01	알닐람 파마슈티칼스 인코포레이티드	트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
JP6836987B2 (ja)	2014-09-05	2021-03-03	フィオファーマシューティカルズコーポレーションＰｈｉｏＰｈａｒｍａｃｅｕｔｉｃａｌｓＣｏｒｐ．	Ｔｙｒまたはｍｍｐ１を標的とする核酸を用いて老化および皮膚障害を処置するための方法
WO2016038550A1 (en)	2014-09-11	2016-03-17	Novartis Ag	Inhibition of prmt5 to treat mtap-deficiency-related diseases
WO2016049163A2 (en)	2014-09-24	2016-03-31	The Broad Institute Inc.	Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049258A2 (en)	2014-09-25	2016-03-31	The Broad Institute Inc.	Functional screening with optimized functional crispr-cas systems
SG11201702662UA (en)	2014-10-02	2017-04-27	Protiva Biotherapeutics Inc	Compositions and methods for silencing hepatitis b virus gene expression
WO2016089883A1 (en)	2014-12-01	2016-06-09	Novartis Ag	Compositions and methods for diagnosis and treatment of prostate cancer
WO2016094880A1 (en)	2014-12-12	2016-06-16	The Broad Institute Inc.	Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094874A1 (en)	2014-12-12	2016-06-16	The Broad Institute Inc.	Escorted and functionalized guides for crispr-cas systems
EP3230452A1 (en)	2014-12-12	2017-10-18	The Broad Institute Inc.	Dead guides for crispr transcription factors
EP3985115A1 (en)	2014-12-12	2022-04-20	The Broad Institute, Inc.	Protected guide rnas (pgrnas)
WO2016100716A1 (en)	2014-12-18	2016-06-23	Vasant Jadhav	Reversirtm compounds
EP3234192B1 (en)	2014-12-19	2021-07-14	The Broad Institute, Inc.	Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en)	2014-12-23	2016-06-30	The Broad Institute Inc.	Rna-targeting system
AU2015369725A1 (en)	2014-12-24	2017-06-29	Massachusetts Institute Of Technology	CRISPR having or associated with destabilization domains
EP3265060B1 (en) *	2015-03-03	2020-10-21	Matinas BioPharma Nanotechnologies, Inc.	Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent
CN104922141B (zh) *	2015-05-28	2016-05-25	厦门成坤生物技术有限公司	一种用于治疗乙型病毒性肝炎的siRNA组合物
WO2016197132A1 (en)	2015-06-04	2016-12-08	Protiva Biotherapeutics Inc.	Treating hepatitis b virus infection using crispr
US20180296537A1 (en)	2015-06-05	2018-10-18	Novartis Ag	Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
EP3430134B1 (en)	2015-06-18	2022-09-21	The Broad Institute, Inc.	Novel crispr enzymes and systems
US9790490B2 (en)	2015-06-18	2017-10-17	The Broad Institute Inc.	CRISPR enzymes and systems
WO2016205749A1 (en)	2015-06-18	2016-12-22	The Broad Institute Inc.	Novel crispr enzymes and systems
WO2016205745A2 (en)	2015-06-18	2016-12-22	The Broad Institute Inc.	Cell sorting
CN109536474A (zh)	2015-06-18	2019-03-29	布罗德研究所有限公司	降低脱靶效应的crispr酶突变
CN114085198A (zh)	2015-06-29	2022-02-25	爱康泰生治疗公司	用于递送核酸的脂质和脂质纳米颗粒制剂
KR20180026739A (ko)	2015-07-06	2018-03-13	알엑스아이 파마슈티칼스 코포레이션	슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
US10808247B2 (en)	2015-07-06	2020-10-20	Phio Pharmaceuticals Corp.	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
WO2017019891A2 (en)	2015-07-29	2017-02-02	Protiva Biotherapeutics, Inc.	Compositions and methods for silencing hepatitis b virus gene expression
HUE051998T2 (hu)	2015-07-31	2021-04-28	Alnylam Pharmaceuticals Inc	Transztiretin (TTR) iRNS készítmények és eljárások azok alkalmazása TTR-asszociált betegségek kezelésére vagy megelõzésére
US9856481B2 (en)	2015-08-13	2018-01-02	Ann & Robert H. Lurie Children's Hospital	MicroRNA treatment of fibrosis
US11214800B2 (en)	2015-08-18	2022-01-04	The Broad Institute, Inc.	Methods and compositions for altering function and structure of chromatin loops and/or domains
WO2017069958A2 (en)	2015-10-09	2017-04-27	The Brigham And Women's Hospital, Inc.	Modulation of novel immune checkpoint targets
JP2018531037A (ja)	2015-10-19	2018-10-25	アールエックスアイファーマシューティカルズコーポレーション	長い非コードｒｎａを標的とする減少したサイズの自己送達型核酸化合物
KR20180133374A (ko)	2015-10-22	2018-12-14	더 브로드 인스티튜트, 인코퍼레이티드	타입 vi-b crispr 효소 및 시스템
US11492670B2 (en)	2015-10-27	2022-11-08	The Broad Institute Inc.	Compositions and methods for targeting cancer-specific sequence variations
WO2017075465A1 (en)	2015-10-28	2017-05-04	The Broad Institute Inc.	Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en)	2015-10-28	2017-05-04	The Broad Institute Inc.	Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
LT3368507T (lt)	2015-10-28	2023-03-10	Acuitas Therapeutics Inc.	Nauji lipidai ir lipidų nanodalelių kompozicijos, skirtos nukleorūgščių tiekimui
WO2017075478A2 (en)	2015-10-28	2017-05-04	The Broad Institute Inc.	Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
EP3397261A4 (en)	2015-11-30	2019-07-03	Flagship Pioneering Innovations V, Inc.	METHODS AND COMPOSITIONS RELATING TO THE CHONDRISOMES
WO2017096326A1 (en)	2015-12-02	2017-06-08	Massachusetts Institute Of Technology	Method for efficient generation of neurons from non-neuronal cells
WO2017106657A1 (en)	2015-12-18	2017-06-22	The Broad Institute Inc.	Novel crispr enzymes and systems
EP3936153A1 (en)	2016-01-11	2022-01-12	Celator Pharmaceuticals, Inc.	Inhibiting ataxia telangiectasia and rad3-related protein (atr)
AU2017257274B2 (en)	2016-04-19	2023-07-13	Massachusetts Institute Of Technology	Novel CRISPR enzymes and systems
CN110382692A (zh)	2016-04-19	2019-10-25	博德研究所	新型crispr酶以及***
US11286478B2 (en)	2016-04-19	2022-03-29	The Broad Institute, Inc.	Cpf1 complexes with reduced indel activity
KR20230156150A (ko)	2016-06-17	2023-11-13	더 브로드 인스티튜트, 인코퍼레이티드	제vi형 crispr 오솔로그 및 시스템
US20210222164A1 (en)	2016-06-29	2021-07-22	The Broad Institute, Inc.	Crispr-cas systems having destabilization domain
US11191849B2 (en)	2016-06-30	2021-12-07	Arbutus Biopharma Corporation	Compositions and methods for delivering messenger RNA
US20200283743A1 (en)	2016-08-17	2020-09-10	The Broad Institute, Inc.	Novel crispr enzymes and systems
US11352647B2 (en)	2016-08-17	2022-06-07	The Broad Institute, Inc.	Crispr enzymes and systems
WO2018039131A1 (en) *	2016-08-22	2018-03-01	Protiva Biotherapeutics, Inc.	Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
US20190262399A1 (en)	2016-09-07	2019-08-29	The Broad Institute, Inc.	Compositions and methods for evaluating and modulating immune responses
WO2018047148A1 (en)	2016-09-12	2018-03-15	Novartis Ag	Compounds for the inhibition of mirna
WO2018067991A1 (en)	2016-10-07	2018-04-12	The Brigham And Women's Hospital, Inc.	Modulation of novel immune checkpoint targets
EP3532103A1 (en)	2016-10-26	2019-09-04	Acuitas Therapeutics, Inc.	Lipid nanoparticle formulations
EP3535396A1 (en)	2016-11-01	2019-09-11	Novartis AG	Methods and compositions for enhancing gene editing
US10526284B2 (en) *	2016-12-21	2020-01-07	Arcturus Therapeutics, Inc.	Ionizable cationic lipid for RNA delivery
JP2020511141A (ja)	2017-03-15	2020-04-16	ザ・ブロード・インスティテュート・インコーポレイテッド	新規Ｃａｓ１３ｂオルソログＣＲＩＳＰＲ酵素及び系
US11840711B2 (en)	2017-04-12	2023-12-12	The Broad Institute, Inc.	Type VI CRISPR orthologs and systems
WO2018191719A1 (en)	2017-04-13	2018-10-18	Acuitas Therapeutics, Inc.	Lipid delivery of therapeutic agents to adipose tissue
WO2018191657A1 (en)	2017-04-13	2018-10-18	Acuitas Therapeutics, Inc.	Lipids for delivery of active agents
US20200405639A1 (en)	2017-04-14	2020-12-31	The Broad Institute, Inc.	Novel delivery of large payloads
CN116693411A (zh)	2017-04-28	2023-09-05	爱康泰生治疗公司	用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
WO2018204777A2 (en)	2017-05-05	2018-11-08	The Broad Institute, Inc.	Methods for identification and modification of lncrna associated with target genotypes and phenotypes
BR112019023323A2 (pt)	2017-05-08	2020-07-21	Flagship Pioneering Innovations V, Inc.	composições para facilitar a fusão de membrana e usos das mesmas
RU2020100074A (ru)	2017-06-13	2021-08-03	Флэгшип Пайониринг Инновейшнз V, Инк.	Композиции, содержащие куроны, и пути их применения
WO2019016772A2 (en)	2017-07-21	2019-01-24	Novartis Ag	COMPOSITIONS AND METHODS FOR TREATING CANCER
WO2019036008A1 (en)	2017-08-16	2019-02-21	Acuitas Therapeutics, Inc.	LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
US11524932B2 (en)	2017-08-17	2022-12-13	Acuitas Therapeutics, Inc.	Lipids for use in lipid nanoparticle formulations
US11542225B2 (en)	2017-08-17	2023-01-03	Acuitas Therapeutics, Inc.	Lipids for use in lipid nanoparticle formulations
WO2019046809A1 (en)	2017-08-31	2019-03-07	Modernatx, Inc.	METHODS OF MANUFACTURING LIPID NANOPARTICLES
MX2020002648A (es)	2017-09-11	2020-07-22	Arrowhead Pharmaceuticals Inc	Agentes de iarn y composiciones para inhibir la expresion de la apolipoproteina c-iii (apoc3).
JP2021508333A (ja)	2017-09-19	2021-03-04	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	トランスサイレチン（ｔｔｒ）媒介アミロイドーシスの治療用組成物及び方法
JP2020535802A (ja)	2017-09-21	2020-12-10	ザ・ブロード・インスティテュート・インコーポレイテッド	標的化核酸編集のための系、方法、及び組成物
EP3692152A4 (en)	2017-10-04	2021-12-01	The Broad Institute, Inc.	PROCESSES AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF CHROMATIN LOOPS AND / OR DOMAINS
WO2019089803A1 (en)	2017-10-31	2019-05-09	The Broad Institute, Inc.	Methods and compositions for studying cell evolution
WO2019089828A1 (en)	2017-10-31	2019-05-09	Acuitas Therapeutics, Inc.	Lamellar lipid nanoparticles
EP3707278A1 (en)	2017-11-09	2020-09-16	Alnylam Pharmaceuticals Inc.	Assays and methods for determining expression of the lect2 gene
EP3710039A4 (en)	2017-11-13	2021-08-04	The Broad Institute, Inc.	METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH
TW201936201A (zh)	2017-12-14	2019-09-16	美商堅固生物科技公司	基因之非病毒生產及遞送
EA202091513A1 (ru)	2017-12-19	2020-09-09	Янссен Сайенсиз Айрлэнд Анлимитед Компани	Вакцины против вируса гепатита b (hbv) и их применение
WO2019150309A1 (en)	2018-02-02	2019-08-08	Hammack Scott	Modulators of gpr68 and uses thereof for treating and preventing diseases
EP3788138A1 (en)	2018-05-02	2021-03-10	Novartis AG	Regulators of human pluripotent stem cells and uses thereof
US20210163944A1 (en)	2018-08-07	2021-06-03	The Broad Institute, Inc.	Novel cas12b enzymes and systems
US20210348162A1 (en)	2018-08-16	2021-11-11	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
US20210317429A1 (en)	2018-08-20	2021-10-14	The Broad Institute, Inc.	Methods and compositions for optochemical control of crispr-cas9
CA3113449A1 (en)	2018-09-21	2020-03-26	Acuitas Therapeutics, Inc.	Systems and methods for manufacturing lipid nanoparticles and liposomes
KR20210068093A (ko) *	2018-09-28	2021-06-08	넛크래커 테라퓨틱스 인코포레이티드	핵산 전달을 위한 지질화 양이온성 펩타이드 화합물을 포함하는 지질 나노입자 제형
WO2020077007A1 (en)	2018-10-09	2020-04-16	The University Of British Columbia	Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
WO2020097493A1 (en) *	2018-11-09	2020-05-14	Arbutus Biopharma Corporation	Negatively charged peg-lipid conjugates
US11166996B2 (en)	2018-12-12	2021-11-09	Flagship Pioneering Innovations V, Inc.	Anellovirus compositions and methods of use
SI3897672T1 (sl)	2018-12-20	2024-02-29	Humabs Biomed Sa	Kombinirana terapija HBV
KR20210138569A (ko)	2019-01-11	2021-11-19	아퀴타스 테라퓨틱스 인크.	활성제의 지질 나노입자 전달을 위한 지질
US20220177863A1 (en)	2019-03-18	2022-06-09	The Broad Institute, Inc.	Type vii crispr proteins and systems
WO2020236972A2 (en)	2019-05-20	2020-11-26	The Broad Institute, Inc.	Non-class i multi-component nucleic acid targeting systems
JP2022536850A (ja)	2019-06-18	2022-08-19	ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー	Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
KR20220042116A (ko)	2019-06-18	2022-04-04	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
WO2020255010A1 (en)	2019-06-18	2020-12-24	Janssen Sciences Ireland Unlimited Company	Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
EP3986915A1 (en)	2019-06-18	2022-04-27	Janssen Sciences Ireland Unlimited Company	Recombinant interleukin 12 construct and uses thereof
CA3143634A1 (en)	2019-06-18	2020-12-24	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
CA3143631A1 (en)	2019-06-20	2020-12-24	Janssen Sciences Ireland Unlimited Company	Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
BR112022002708A2 (pt)	2019-08-14	2022-05-31	Acuitas Therapeutics Inc	Nanopartículas lipídicas aperfeiçoadas para a liberação de ácidos nucleicos
EP4025694A1 (en)	2019-09-03	2022-07-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
EP4038189A1 (en)	2019-10-04	2022-08-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing ugt1a1 gene expression
US20230040920A1 (en)	2019-11-01	2023-02-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
CN115135765A (zh)	2019-11-08	2022-09-30	菲奥医药公司	用于免疫治疗的靶向含布罗莫结构域之蛋白4(brd4)的经化学修饰的寡核苷酸
US20230089478A1 (en)	2019-12-31	2023-03-23	Phio Pharmaceuticals Corp.	Chemically modified oligonucleotides with improved systemic delivery
CN115427571A (zh)	2020-02-10	2022-12-02	阿尔尼拉姆医药品有限公司	沉默vegf-a表达的组合物和方法
EP4127171A2 (en)	2020-03-30	2023-02-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
IL296781A (en)	2020-03-30	2022-11-01	BioNTech SE	RNA compositions targeting claudin-18.2
BR112022020145A2 (pt)	2020-04-06	2023-01-03	Alnylam Pharmaceuticals Inc	Composições e métodos para silenciamento da expressão de myoc
JP2023521094A (ja)	2020-04-07	2023-05-23	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｓｃｎ９ａ発現をサイレンシングするための組成物および方法
CN111494641B (zh) *	2020-04-22	2021-08-03	南开大学	肿瘤微环境响应性的表面电荷可反转纳米药物递送载体
EP4153746A1 (en)	2020-05-21	2023-03-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting marc1 gene expression
CA3187353A1 (en)	2020-06-15	2021-12-23	Research Institute At Nationwide Children's Hospital	Adeno-associated virus vector delivery for muscular dystrophies
BR112022026316A2 (pt)	2020-06-24	2023-03-07	Vir Biotechnology Inc	Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
EP4178613A1 (en)	2020-07-08	2023-05-17	Janssen Sciences Ireland Unlimited Company	Rna replicon vaccines against hbv
BR112023000327A2 (pt)	2020-07-16	2023-01-31	Acuitas Therapeutics Inc	Lipídeos catiônicos para o uso em nanopartículas lipídicas
US11771652B2 (en)	2020-11-06	2023-10-03	Sanofi	Lipid nanoparticles for delivering mRNA vaccines
CN117098541A (zh)	2020-11-25	2023-11-21	阿卡格拉医药公司	用于递送核酸的脂质纳米粒及相关使用方法
WO2022133230A1 (en)	2020-12-18	2022-06-23	Janssen Pharmaceuticals, Inc.	Combination therapy for treating hepatitis b virus infection
JP2024501022A (ja)	2020-12-28	2024-01-10	アークトゥルスセラピューティクス，インコーポレイテッド	Ｈｂｖを標的とする転写活性化因子様エフェクターヌクレアーゼ（ｔａｌｅｎ）
WO2022215036A1 (en)	2021-04-08	2022-10-13	Vaxthera Sas	Coronavirus vaccine comprising a mosaic protein
CA3173953A1 (en)	2021-06-11	2023-12-10	Tyson D. BOWEN	Rna polymerase iii promoters and methods of use
AU2022315530A1 (en)	2021-07-20	2024-01-18	Ags Therapeutics Sas	Extracellular vesicles from microalgae, their preparation, and uses
CN117795074A (zh)	2021-08-03	2024-03-29	阿尔尼拉姆医药品有限公司	转甲状腺素蛋白（TTR）iRNA组合物和其使用方法
KR20240041973A (ko)	2021-08-04	2024-04-01	피오 파마슈티칼스 코프.	화학적으로 변형된 올리고뉴클레오티드
WO2023015264A1 (en)	2021-08-04	2023-02-09	Phio Pharmaceuticals Corp.	Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
WO2023023055A1 (en)	2021-08-16	2023-02-23	Renagade Therapeutics Management Inc.	Compositions and methods for optimizing tropism of delivery systems for rna
CA3232386A1 (en)	2021-09-14	2023-03-23	Renagade Therapeutics Management Inc.	Cyclic lipids and methods of use thereof
CA3231523A1 (en)	2021-09-14	2023-03-23	Renagade Therapeutics Management Inc.	Acyclic lipids and methods of use thereof
AU2022368907A1 (en)	2021-10-20	2024-05-02	University Of Copenhagen	Rejuvenation treatment of age-related white matter loss
WO2023081756A1 (en)	2021-11-03	2023-05-11	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Precise genome editing using retrons
WO2023091490A1 (en)	2021-11-16	2023-05-25	Senda Biosciences, Inc.	Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2023091787A1 (en)	2021-11-22	2023-05-25	Senda Biosciences, Inc.	Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2023122752A1 (en)	2021-12-23	2023-06-29	Renagade Therapeutics Management Inc.	Constrained lipids and methods of use thereof
WO2023141602A2 (en)	2022-01-21	2023-07-27	Renagade Therapeutics Management Inc.	Engineered retrons and methods of use
WO2023147090A1 (en)	2022-01-27	2023-08-03	BioNTech SE	Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2023144127A1 (en)	2022-01-31	2023-08-03	Ags Therapeutics Sas	Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023144798A1 (en)	2022-01-31	2023-08-03	Genevant Sciences Gmbh	Ionizable cationic lipids for lipid nanoparticles
WO2023183616A1 (en)	2022-03-25	2023-09-28	Senda Biosciences, Inc.	Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2023196818A1 (en)	2022-04-04	2023-10-12	The Regents Of The University Of California	Genetic complementation compositions and methods
WO2023196931A1 (en)	2022-04-07	2023-10-12	Renagade Therapeutics Management Inc.	Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
WO2023215481A1 (en)	2022-05-05	2023-11-09	The Board Of Trustees Of The Leland Stanford Junior University	INTERFERING RNA THERAPY FOR PLN-R14del CARDIOMYOPATHY
WO2023218420A1 (en)	2022-05-13	2023-11-16	Janssen Pharmaceuticals, Inc.	Mrna compositions for inducing latent hiv-1 reversal
WO2023218431A1 (en)	2022-05-13	2023-11-16	BioNTech SE	Rna compositions targeting hiv
WO2023230295A1 (en)	2022-05-25	2023-11-30	BioNTech SE	Rna compositions for delivery of monkeypox antigens and related methods
WO2023229535A1 (en)	2022-05-27	2023-11-30	Engine Biosciences Pte. Ltd.	Bet polypeptide therapeutic agents for generating synthetic lethality in tumors
WO2023232747A1 (en)	2022-05-30	2023-12-07	BioNTech SE	Complexes for delivery of nucleic acids
WO2023233290A1 (en)	2022-05-31	2023-12-07	Janssen Sciences Ireland Unlimited Company	Rnai agents targeting pd-l1
WO2023232976A1 (en)	2022-06-03	2023-12-07	Ags Therapeutics Sas	Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
WO2024033901A1 (en)	2022-08-12	2024-02-15	LifeEDIT Therapeutics, Inc.	Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2024049979A2 (en)	2022-08-31	2024-03-07	Senda Biosciences, Inc.	Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2024063788A1 (en)	2022-09-23	2024-03-28	BioNTech SE	Compositions for delivery of malaria antigens and related methods
WO2024063789A1 (en)	2022-09-23	2024-03-28	BioNTech SE	Compositions for delivery of malaria antigens and related methods
WO2024064934A1 (en)	2022-09-23	2024-03-28	BioNTech SE	Compositions for delivery of plasmodium csp antigens and related methods
WO2024064931A1 (en)	2022-09-23	2024-03-28	BioNTech SE	Compositions for delivery of liver stage antigens and related methods
WO2024074211A1 (en)	2022-10-06	2024-04-11	BioNTech SE	Rna compositions targeting claudin-18.2
WO2024074634A1 (en)	2022-10-06	2024-04-11	BioNTech SE	Rna compositions targeting claudin-18.2
WO2024088808A1 (en)	2022-10-24	2024-05-02	Ags Therapeutics Sas	Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002087541A1 (en) *	2001-04-30	2002-11-07	Protiva Biotherapeutics Inc.	Lipid-based formulations for gene transfer

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4394448A (en) *	1978-02-24	1983-07-19	Szoka Jr Francis C	Method of inserting DNA into living cells
EP0032578B1 (de) *	1980-01-16	1984-07-25	Hans Georg Prof. Dr. Weder	Verfahren und Dialysiereinrichtung zur Herstellung von Bilayer-Vesikeln und Verwendung der Bilayer-Vesikel
US4598051A (en) *	1980-03-12	1986-07-01	The Regents Of The University Of California	Liposome conjugates and diagnostic methods therewith
US4436052A (en) *	1980-09-15	1984-03-13	Schall William R	Globe-shaped bells with single-piece shells
US4515736A (en) *	1983-05-12	1985-05-07	The Regents Of The University Of California	Method for encapsulating materials into liposomes
US5545412A (en) *	1985-01-07	1996-08-13	Syntex (U.S.A.) Inc.	N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) *	1985-01-07	1990-01-30	Syntex (U.S.A.) Inc.	N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5208036A (en) *	1985-01-07	1993-05-04	Syntex (U.S.A.) Inc.	N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
US5320906A (en) *	1986-12-15	1994-06-14	Vestar, Inc.	Delivery vehicles with amphiphile-associated active ingredient
US5703055A (en) *	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
FR2645866B1 (fr) *	1989-04-17	1991-07-05	Centre Nat Rech Scient	Nouvelles lipopolyamines, leur preparation et leur emploi
US5725871A (en)	1989-08-18	1998-03-10	Danbiosyst Uk Limited	Drug delivery compositions comprising lysophosphoglycerolipid
JPH03126211A (ja)	1989-10-12	1991-05-29	Nippon Chemicon Corp	電解コンデンサ用電解液
US5013556A (en) *	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5225212A (en) *	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
US5707644A (en)	1989-11-04	1998-01-13	Danbiosyst Uk Limited	Small particle compositions for intranasal drug delivery
US5279833A (en)	1990-04-04	1994-01-18	Yale University	Liposomal transfection of nucleic acids into animal cells
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
JP2774417B2 (ja)	1991-08-07	1998-07-09	株式会社ディ・ディ・エス研究所	ペプチド骨格を有する分枝鎖型糖複合体及び微粒子キャリヤー
US5283185A (en)	1991-08-28	1994-02-01	University Of Tennessee Research Corporation	Method for delivering nucleic acids into cells
US5756353A (en)	1991-12-17	1998-05-26	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol-and liposome-based delivery
JPH07502510A (ja)	1991-12-17	1995-03-16	ザリージェンツオブザユニバーシティオブカリフォルニア	嚢胞性繊維症膜貫通型コンダクタンス調節活性（ｃｆｔｒ）のための遺伝子治療
US5858784A (en)	1991-12-17	1999-01-12	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0672178A4 (en) *	1992-02-19	1996-03-20	Baylor College Medicine	CELL GROWTH MODULATION WITH OLIGONUCLEOTIDS.
WO1993023011A1 (en)	1992-05-18	1993-11-25	Minnesota Mining And Manufacturing Company	Transmucosal drug delivery device
CA2134773A1 (en)	1992-06-04	1993-12-09	Robert J. Debs	Methods and compositions for in vivo gene therapy
US5792451A (en)	1994-03-02	1998-08-11	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
JP2854203B2 (ja)	1992-09-03	1999-02-03	株式会社ディ・ディ・エス研究所	リポソームの製造法
JP3626187B2 (ja)	1993-06-07	2005-03-02	バイカルインコーポレイテッド	遺伝子治療に適するプラスミド
US5578475A (en) *	1993-07-12	1996-11-26	Life Technologies, Inc.	Composition and methods for transfecting eukaryotic cells
US5543158A (en)	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
US5426039A (en)	1993-09-08	1995-06-20	Bio-Rad Laboratories, Inc.	Direct molecular cloning of primer extended DNA containing an alkane diol
FR2714830B1 (fr)	1994-01-10	1996-03-22	Rhone Poulenc Rorer Sa	Composition contenant des acides nucléiques, préparation et utilisations.
AU696881B2 (en)	1994-06-22	1998-09-24	Megabios Corporation	Cationic amphiphiles
FR2722506B1 (fr)	1994-07-13	1996-08-14	Rhone Poulenc Rorer Sa	Composition contenant des acides nucleiques, preparation et utilisations
DE69527206T2 (de)	1994-09-30	2003-02-27	Inex Pharmaceuticals Corp	Mittel zum einbringen polyanionischer materialien in zellen
US5820873A (en)	1994-09-30	1998-10-13	The University Of British Columbia	Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en)	1994-09-30	1999-03-23	The University Of British Columbia	Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en)	1994-09-30	1998-05-19	Inex Pharmaceuticals Corporation	Compositions for the introduction of polyanionic materials into cells
US5580579A (en)	1995-02-15	1996-12-03	Nano Systems L.L.C.	Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5962428A (en)	1995-03-30	1999-10-05	Apollon, Inc.	Compositions and methods for delivery of genetic material
IE80468B1 (en)	1995-04-04	1998-07-29	Elan Corp Plc	Controlled release biodegradable nanoparticles containing insulin
JP3488340B2 (ja) *	1995-05-15	2004-01-19	株式会社リコー	可逆性感熱発色組成物およびそれを用いた可逆性記録媒体
ES2231819T3 (es)	1995-06-07	2005-05-16	Inex Pharmaceuticals Corp	Particulas de lipido-acido nucleico preparadas a traves de un intermedio complejo de lipido-acido nucleico hidrofobo y uso para transferir genes.
US5981501A (en)	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) *	1995-06-07	2008-09-09	The University Of British Columbia	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5705385A (en)	1995-06-07	1998-01-06	Inex Pharmaceuticals Corporation	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5811406A (en)	1995-06-07	1998-09-22	Regents Of The University Of California	Dry powder formulations of polynucleotide complexes
US5817856A (en) *	1995-12-11	1998-10-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Radiation-protective phospholipid and method
US6284267B1 (en) *	1996-08-14	2001-09-04	Nutrimed Biotech	Amphiphilic materials and liposome formulations thereof
US6210707B1 (en)	1996-11-12	2001-04-03	The Regents Of The University Of California	Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6287591B1 (en) *	1997-05-14	2001-09-11	Inex Pharmaceuticals Corp.	Charged therapeutic agents encapsulated in lipid particles containing four lipid components
AU7490098A (en)	1997-05-15	1998-12-08	Genzyme Corporation	Cationic amphiphile formulations
US20030073640A1 (en)	1997-07-23	2003-04-17	Ribozyme Pharmaceuticals, Inc.	Novel compositions for the delivery of negatively charged molecules
CA2309727C (en)	1997-10-10	2012-12-04	Inex Pharmaceuticals Corporation	Methods for encapsulating nucleic acids in lipid bilayers
US6320017B1 (en)	1997-12-23	2001-11-20	Inex Pharmaceuticals Corp.	Polyamide oligomers
US6410328B1 (en) *	1998-02-03	2002-06-25	Protiva Biotherapeutics Inc.	Sensitizing cells to compounds using lipid-mediated gene and compound delivery
AUPP249298A0 (en)	1998-03-20	1998-04-23	Ag-Gene Australia Limited	Synthetic genes and genetic constructs comprising same I
CA2271582A1 (en)	1998-05-14	1999-11-14	Sean C. Semple	Method for administration of therapeutic agents, including antisense, with repeat dosing
US6429200B1 (en)	1998-07-17	2002-08-06	Mirus Corporation	Reverse micelles for delivery of nucleic acids
CA2335393C (en)	1998-07-20	2008-09-23	Inex Pharmaceuticals Corporation	Liposomal encapsulated nucleic acid-complexes
US6900049B2 (en) *	1998-09-10	2005-05-31	Cell Genesys, Inc.	Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6649780B1 (en) *	1998-12-22	2003-11-18	Valentis, Inc.	Cationic lipids
CA2370690A1 (en)	1999-04-20	2000-10-26	The University Of British Columbia	Cationic peg-lipids and methods of use
US6696424B1 (en) *	1999-05-28	2004-02-24	Vical Incorporated	Cytofectin dimers and methods of use thereof
US20010048940A1 (en) *	1999-06-18	2001-12-06	Jennifer D. Tousignant	Cationic amphiphile micellar complexes
KR100758158B1 (ko) *	1999-07-14	2007-09-12	알자 코포레이션	중성 지질중합체 및 그를 함유하는 리포솜 조성물
WO2001005373A1 (en) *	1999-07-15	2001-01-25	Inex Pharmaceuticals Corp.	Methods and apparatus for preparation of lipid vesicles
US6458382B1 (en)	1999-11-12	2002-10-01	Mirus Corporation	Nucleic acid transfer complexes
JP4782966B2 (ja)	2000-01-10	2011-09-28	イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド	疾患の治療における脂質コンジュゲートの使用
NZ553687A (en) *	2000-03-30	2010-03-26	Whitehead Biomedical Inst	RNA sequence-specific mediators of RNA interference
US7189705B2 (en)	2000-04-20	2007-03-13	The University Of British Columbia	Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US20030082103A1 (en)	2000-10-11	2003-05-01	Targesome, Inc.	Targeted therapeutic lipid constructs having cell surface targets
EP1328254B1 (en) *	2000-10-25	2007-02-21	The University Of British Columbia	Lipid formulations for target delivery
US20020081736A1 (en)	2000-11-03	2002-06-27	Conroy Susan E.	Nucleic acid delivery
PT1407044E (pt) *	2000-12-01	2008-01-02	Max Planck Ges Zur Forderung W	Moléculas curtas de arn que medeiam a interferência de arn
EP1386004A4 (en) *	2001-04-05	2005-02-16	Ribozyme Pharm Inc	MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US20030026831A1 (en)	2001-04-20	2003-02-06	Aparna Lakkaraju	Anionic liposomes for delivery of bioactive agents
US20040142892A1 (en) *	2001-04-30	2004-07-22	The University Of British Columbia	Autogene nucleic acids encoding a secretable RNA polymerase
US20040063654A1 (en) *	2001-11-02	2004-04-01	Davis Mark E.	Methods and compositions for therapeutic use of RNA interference
US8496961B2 (en)	2002-05-15	2013-07-30	Sutter West Bay Hospital	Delivery of nucleic acid-like compounds
EP1519714B1 (en) *	2002-06-28	2010-10-20	Protiva Biotherapeutics Inc.	Method and apparatus for producing liposomes
CA2513623A1 (en) *	2003-01-16	2004-08-05	The Trustees Of The University Of Pennsylvania	Compositions and methods for sirna inhibition of icam-1
US7803781B2 (en) *	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
AU2004246905B2 (en)	2003-06-18	2010-01-21	Biolab Ltd.	Sphingoid polyalkylamine conjugates for vaccination
EP2567693B1 (en)	2003-07-16	2015-10-21	Protiva Biotherapeutics Inc.	Lipid encapsulated interfering RNA
NZ592917A (en)	2003-09-15	2012-12-21	Protiva Biotherapeutics Inc	Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
AU2005252273B2 (en) *	2004-06-07	2011-04-28	Arbutus Biopharma Corporation	Lipid encapsulated interfering RNA
AU2005251403B2 (en)	2004-06-07	2011-09-01	Arbutus Biopharma Corporation	Cationic lipids and methods of use
CA2572439A1 (en) *	2004-07-02	2006-01-12	Protiva Biotherapeutics, Inc.	Immunostimulatory sirna molecules and uses therefor
EP1937213B1 (en) *	2005-07-27	2017-10-25	Protiva Biotherapeutics Inc.	Systems and methods for manufacturing liposomes
EP2770057A1 (en) *	2008-04-15	2014-08-27	Protiva Biotherapeutics Inc.	Silencing of CSN5 gene expression using interfering RNA
JP5766188B2 (ja) *	2009-07-01	2015-08-19	プロチババイオセラピューティクスインコーポレイティッド	固形腫瘍に治療剤を送達するための脂質製剤

2004
- 2004-07-16 EP EP12191154.9A patent/EP2567693B1/en active Active
- 2004-07-16 SG SG2013033162A patent/SG190613A1/en unknown
- 2004-07-16 WO PCT/CA2004/001051 patent/WO2005007196A2/en active Application Filing
- 2004-07-16 US US10/893,121 patent/US20050064595A1/en not_active Abandoned
- 2004-07-16 EP EP04761574.5A patent/EP1648519B1/en active Active
- 2004-07-16 JP JP2006519738A patent/JP4951338B2/ja not_active Expired - Fee Related
- 2004-07-16 CA CA2532228A patent/CA2532228C/en active Active
- 2004-07-16 AU AU2004257373A patent/AU2004257373B2/en active Active
- 2004-07-16 KR KR1020067000992A patent/KR101168440B1/ko active IP Right Grant
- 2004-07-16 CN CN2004800251682A patent/CN101291653B/zh active Active
- 2004-07-16 ES ES12191154.9T patent/ES2559828T3/es active Active
- 2004-07-16 NZ NZ544637A patent/NZ544637A/en unknown
2006
- 2006-01-10 IL IL173052A patent/IL173052A/en active IP Right Grant
- 2006-06-27 US US11/426,907 patent/US7982027B2/en active Active
2009
- 2009-04-21 HK HK09103668.6A patent/HK1123751A1/xx unknown
2011
- 2011-01-21 JP JP2011010545A patent/JP5784914B2/ja active Active
- 2011-03-31 AU AU2011201463A patent/AU2011201463A1/en not_active Abandoned
- 2011-06-24 US US13/168,543 patent/US20120058188A1/en not_active Abandoned
2013
- 2013-04-11 JP JP2013083198A patent/JP2013136645A/ja not_active Withdrawn
2015
- 2015-03-12 IL IL237721A patent/IL237721B/en active IP Right Grant
- 2015-05-07 JP JP2015094544A patent/JP5977394B2/ja active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002087541A1 (en) *	2001-04-30	2002-11-07	Protiva Biotherapeutics Inc.	Lipid-based formulations for gene transfer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2019212288A1 (ko) *	2018-05-04	2019-11-07	주식회사 삼양바이오팜	Messenger rna 전달용 고분자 나노입자 조성물 및 그 제조방법

Also Published As

Publication number	Publication date
JP2007528863A (ja)	2007-10-18
IL173052A (en)	2015-03-31
JP2011126892A (ja)	2011-06-30
EP2567693B1 (en)	2015-10-21
WO2005007196A3 (en)	2008-01-03
IL173052A0 (en)	2006-06-11
US20060240093A1 (en)	2006-10-26
JP2013136645A (ja)	2013-07-11
CA2532228A1 (en)	2005-01-27
SG190613A1 (en)	2013-06-28
CN101291653A (zh)	2008-10-22
JP4951338B2 (ja)	2012-06-13
JP2015143273A (ja)	2015-08-06
AU2004257373A1 (en)	2005-01-27
IL237721B (en)	2018-02-28
US20120058188A1 (en)	2012-03-08
AU2011201463A1 (en)	2011-04-21
CN101291653B (zh)	2012-06-27
WO2005007196A2 (en)	2005-01-27
CA2532228C (en)	2017-02-14
KR20060028655A (ko)	2006-03-30
HK1123751A1 (en)	2009-06-26
US20050064595A1 (en)	2005-03-24
EP1648519A2 (en)	2006-04-26
EP2567693A1 (en)	2013-03-13
NZ544637A (en)	2010-04-30
US7982027B2 (en)	2011-07-19
AU2004257373B2 (en)	2011-03-24
JP5784914B2 (ja)	2015-09-24
ES2559828T3 (es)	2016-02-16
JP5977394B2 (ja)	2016-08-24
EP1648519B1 (en)	2014-10-08

Legal Events

Date	Code	Title	Description
2009-07-16	A201	Request for examination
2011-07-01	E902	Notification of reason for refusal
2012-05-09	E701	Decision to grant or registration of patent right
2012-07-18	GRNT	Written decision to grant
2015-06-19	FPAY	Annual fee payment	Payment date: 20150619 Year of fee payment: 4
2016-06-30	FPAY	Annual fee payment	Payment date: 20160630 Year of fee payment: 5
2017-07-04	FPAY	Annual fee payment	Payment date: 20170704 Year of fee payment: 6
2018-07-16	FPAY	Annual fee payment	Payment date: 20180717 Year of fee payment: 7

Publication	Publication Date	Title
KR101168440B1 (ko)	2012-07-27	지질 캡슐화된 간섭 ｒｎａ
US9926560B2 (en)	2018-03-27	Lipid encapsulating interfering RNA
US7807815B2 (en)	2010-10-05	Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA
JP4842821B2 (ja)	2011-12-21	ポリエチレングリコール修飾脂質化合物およびその使用
NZ583623A (en)	2011-09-30	Lipid encapsulated interfering RNA

KR101168440B1 - 지질 캡슐화된 간섭 ｒｎａ - Google Patents

Info

Links

Images

Classifications

Applications Claiming Priority (7)

Publications (2)

Family

ID=34084527

Family Applications (1)

Country Status (13)

Cited By (1)

Families Citing this family (366)

Citations (1)

Family Cites Families (97)

Patent Citations (1)

Cited By (1)

Also Published As

Similar Documents

Legal Events